Medicine and Dentistry
Biological Marker
100%
Hepatocellular Carcinoma
100%
Ipilimumab
100%
Nivolumab
100%
Immunotherapy
80%
Neoplasm
60%
Biopsy Technique
40%
Clinical Trial
40%
Malignant Neoplasm
20%
Tumor Marker
20%
Immunity
20%
Immunocompetent Cell
20%
Immune Cell Infiltration
20%
Liver Fibrosis
20%
Neoadjuvant Therapy
20%
CD8 Antigen
20%
Predictive Marker
20%
Fibrosis
20%
Tumor Necrosis
20%
Rank Sum Test
20%
Cell Activation
20%
Granzyme B
20%
Programmed Death-Ligand 1
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Biological Marker
100%
Ipilimumab
100%
Nivolumab
100%
Immunotherapy
80%
Neoplasm
60%
Clinical Trial
40%
Malignant Neoplasm
20%
Fibrosis
20%
Liver Fibrosis
20%
Tumor Marker
20%
CD8 Antigen
20%
Tumor Necrosis
20%
Granzyme B
20%
Immunology and Microbiology
Immunotherapy
100%
Ipilimumab
100%
Nivolumab
100%
Tumor Volume
50%
CD8
25%
Immunocompetent Cell
25%
Immunity
25%
Immune Cell Infiltration
25%
Programmed Death-Ligand 1
25%
Granzyme B
25%
Cell Activation
25%